Zimmer Biomet Holdings, Inc.

• ZBH Stock Price 24h change: +2.06%. From 87.47 USD to 89.28 USD. The price rebounded slightly following a period of weakness, though overall sentiment remains cautious due to previous downgrades and concerns over 2026 sales growth.
• From a technical perspective, ZBH is in a "bearish consolidation" phase: technical indicators suggest a Strong Sell as the stock remains below its 50-day ($91.60) and 200-day ($96.54) moving averages. RSI at 47.5 indicates neutral momentum, but short-term oscillators suggest the market is struggling to regain bullish traction after multi-year lows.
• Zimmer Biomet announced on January 15 that it will webcast its fourth-quarter 2025 financial results on February 10, 2026.
• Analysts at Goldman Sachs recently downgraded ZBH to a "Sell," citing a tempered outlook for sales growth heading into 2026.
• A company director reported acquiring approximately 304 phantom stock units as part of a deferred compensation plan, bringing their total to over 31,500 units.
• Boston Scientific announced an agreement to acquire Valencia, a developer of medical devices for incontinence, highlighting ongoing M&A activity in the medtech sector.
• The FDA has exempted more wearable and AI-driven medical device features from certain oversight requirements, aiming to accelerate innovation in digital health products.

• ZBH Stock Price 24h change: +1.02%. From 88.34 USD to 89.24 USD.
• The stock's modest gain on January 14 reflects a slight recovery from recent volatility, though it remains under pressure following the J.P. Morgan Healthcare Conference where CEO Ivan Tornos delayed formal Q1 guidance until February 10, 2026, creating short-term strategic uncertainty.
• From a technical perspective, ZBH is in a "weak-to-neutral" phase. It is currently trading below its 50-day moving average ($91.60) and 200-day moving average ($96.54). While the RSI has recently been as low as 30 (oversold), suggesting a potential bounce, current sentiment remains weak with a 30:1 risk-reward setup targeting further downside toward $84.04 support.
• Zimmer Biomet announced it will webcast its fourth-quarter 2025 financial results on February 10, 2026, a date now critical for investors seeking clarity on the company's 2026 operational roadmap.
• Bernstein recently maintained a "Market Perform" rating on ZBH but slightly raised the price target to $99 from $97, reflecting a cautious view on the stock's recovery potential amid operational shifts.
• Analysts highlight that ZBH is trading at a significant discount (approx. 46%) to its estimated intrinsic value of $165.20, though financial stress indicators (Altman Z-Score of 2.4) keep long-term optimism tempered.
• Boston Scientific announced an agreement to acquire Valencia, an incontinence device maker, signaling continued consolidation and targeted M&A activity within the medical technology sector.
• Medtronic reported strong 5.5% organic revenue growth in early 2026, driven by a 71% surge in its cardiac ablation franchise, highlighting a robust demand environment for high-innovation medical platforms.